floo-OX-uh-teen
BEERS REMS
Contraindicated in:
Use Cautiously in:
May ↑ risk of suicide attempt/ideation especially during early treatment or dose adjustment; this risk appears to be greater in adolescents or children
;CV: chest pain, palpitations, QT interval prolongation, TORSADES DE POINTES
Derm: ↑sweating, pruritus, erythema nodosum, flushing, rash
EENT: mydriasis, stuffy nose, visual disturbances
Endo: SIADH, dysmenorrhea, hot flush
F and E: hyponatremia
GI: diarrhea, abdominal pain, abnormal taste, anorexia, constipation, dry mouth, dyspepsia, nausea, vomiting, weight loss
GU: ↓libido, delayed/absent orgasm, ejaculatory delay/failure, erectile dysfunction, urinary frequency
Hemat: BLEEDING
MS: arthralgia, back pain, myalgia
Neuro: anxiety, drowsiness, headache, insomnia, nervousness, tremor, abnormal dreams, dizziness, fatigue, hypomania, mania, NEUROLEPTIC MALIGNANT SYNDROME, SEIZURES, SUICIDAL THOUGHTS/BEHAVIORS, weakness
Resp: cough
Misc: fever, flu-like syndrome, hypersensitivity reactions, SEROTONIN SYNDROME
Drug-drug:
Drug-Natural Products:
Depression
Obsessive Compulsive Disorder
Panic Disorder
Bulimia Nervosa
Premenstrual Dysphoric Disorder
Depressive Disorders Associated with Bipolar I Disorder
Treatment-Resistant Depression
Therapeutic Classification: antidepressants
Pharmacologic Classification: selective serotonin reuptake inhibitors ssris
Absorption: Well absorbed after oral administration.
Distribution: Crosses the blood-brain barrier.
Protein Binding: 94.5%.
Half-Life: 1–3 days (norfluoxetine 5–7 days).
Advise patient, family, and caregivers to watch for suicidality, especially during early therapy or dose changes. Notify health care provider immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior occur.
NDC Code
